Continuing androgen blacked with addign drugs – pro
EMBARK was the first study designed to determine whether early, combined therapy with enzalutamide plus a luteinising hormone-releasing hormone agonist (LHRHa) or enzalutamide monotherapy is more effective than placebo plus LHRHa in patients with high-risk non-metastatic castration-sensitive prostate cancer. Although the results fo this study and an older metanalysis have recently been questioned, it remains standard practice.
Thlmann CH, Ruessel C, Zillmann R, et al: Abiraterone acetate plus prednisone without continuing LHRH therapy in patients with metastatic chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE trial (NCT02077634). 2019 ASCO Annual Meeting. Abstract 5046. Presented June 1, 2019.
Jha GG, Engle J: Suppression of testosterone production using abiraterone acetate with or without androgen deprivation therapy in metastatic castration-resistant prostate cancer. 2019 ASCO Annual Meeting. Abstract 5049. Presented June 1, 2019.
Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, Haas GP, Shore ND. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021 Aug 12;11(8)